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Abstract 
Mechanisms underlying the pathogenesis of ischemia/reperfusion injury are particularly complex, multifactorial and 
highly interconnected. A complex and entangled interaction is also emerging between platelet function, antiplatelet 
drugs, coronary diseases and ischemia/reperfusion injury, especially in diabetic conditions. Here we briefly summarize 
features of antiplatelet therapy in type 2 diabetes (T2DM). We also treat the influence of T2DM on ischemia/reperfu-
sion injury and how anti-platelet therapies affect post-ischemic myocardial damage through pleiotropic properties 
not related to their anti-aggregating effects. miRNA-based signature associated with T2DM and its cardiovascular dis-
ease complications are also briefly considered. Influence of anti-platelet therapies and different effects of healthy and 
diabetic platelets on ischemia/reperfusion injury need to be further clarified in order to enhance patient benefits from 
antiplatelet therapy and revascularization. Here we provide insight on the difficulty to reduce the cardiovascular risk in 
diabetic patients and report novel information on the cardioprotective role of widely used anti-aggregant drugs.
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Background
Using population-wide preventive strategies, most car-
diovascular diseases (CVDs) can be avoided by modify-
ing behavioural risk factors, diet, physical activity and 
harmful use of tobacco, drugs and alcohol. However, 
at the  individual level, secondary prevention of CVDs 
in those with established risk factors and treatment 
of  comorbidities, including diabetes, with appropri-
ate medications are necessary. Type 2 diabetes mellitus 
(T2DM) is an expanding global pandemia character-
ized by a very high cardiovascular risk [1, 2] and diabetic 
patients without previous cardiovascular events show 
similar risk for cardiac mortality as non-diabetic subjects 
after myocardial infarction [3]. The excess risk for CVDs 
in patients with diabetes needs a multifactorial preven-
tion, including an effective antiplatelet therapy for the 
correction of the thrombotic risk [4, 5].
In this mini-review we briefly analyse the issues of anti-
platelet therapy, and how the pleiotropic effects of this 
therapy and platelets per se may affect ischemia/reperfu-
sion injury (IRI) in T2DM heart.
Aspirin function on platelets
The first-line drug of the anti-aggregating therapy is aspi-
rin, which is used in primary and secondary prevention of 
cardiovascular accidents. As extensively reviewed [6, 7], 
aspirin inhibition of platelet function is mediated by the 
permanent inactivation -due to acetylation of some ser-
ine domains- of Cyclo-Oxygenase-1 (COX-1), an enzyme 
constitutively expressed in platelets, which converts ara-
chidonic acid into Prostaglandin H2 (PGH2), the sub-
strate of the Thromboxane (TX)-synthase, which forms 
TXA2, a very powerful aggregating agent (Fig. 1). Aspi-
rin is about 200-fold more powerful in inhibiting COX-1 
than COX-2, which is inducible by inflammatory stimuli 
and is present in newly formed platelets. Indeed, in plate-
lets the inducible COX-2 normally seems not expressed, 
though small quantities are detectable in mature plate-
lets [8]. Therefore, the role of COX-2 in platelet function 
is not clear and it seems that the selective inhibitors of 
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COX-2 only slightly reduce platelet TXA2 formation [9]. 
Indeed, it has been reported that the very low COX-2 
expression in platelets does not influence the effect of 
aspirin [10].
Inhibition of COX-1 in platelet requires low doses of 
aspirin and platelet aggregability is irreversible as it lasts 
for the lifetime of platelets, which is of about 10  days. 
Aspirin benefits exceed the inhibition of TXA2, since it 
may increase platelet nitric oxide (NO) synthesis, pro-
tects NO from its inactivation, improves endothelial dys-
function, exerts anti-inflammatory effects [11].
Oral anti‑aggregant agents function on platelets
Either for secondary prevention or for subject undergoing 
a revascularization procedure, oral anti-aggregant agents 
have been proposed in the last years: ticlopidine, clopi-
dogrel, prasugrel and ticagrelor. All these agents (either 
classified as thienopyridine or as non-thienopyridine) act 
directly or indirectly inhibiting adenosine diphosphate 
(ADP) receptor  P2Y12 (Fig. 2). Although improved in the 
more recent compounds, the onset of anti-aggregating 
effect of these oral agents may be delayed because they 
are slowly adsorbed and may need to be converted to 
active substances by the liver. Thienopyridines (clopi-
dogrel and prasugrel) require hepatic P450-mediated 
conversion of the pro-drug into its active metabolite 
[12]. Non-thienopyridine  P2Y12 inhibitors (ticagrelor and 
cangrelor) are directly active, but have a long absorption 
time after oral administration, particularly in patients 
receiving opiate analgesia. This delayed onset of activ-
ity may be an issue in the clinical context in which it is 
necessary to minimize the door-to-balloon time. In 
order to render more effective percutaneous coronary 
intervention (PCI) an intravenous  P2Y12 antagonist (i.e. 
cangrelor) may be considered. Cangrelor effects are very 
rapid and reach a very high anti-aggregation effect within 
a few minutes after i.v. administration. All these agents 
prevent the activation  P2Y12, thus avoiding the activation 
of an inhibitory G protein (Gi) by ligands. Consequently, 
adenylate cyclase may increase the intra-platelet con-
centration of cyclic adenosine monophosphate (cAMP). 
Indeed, cAMP levels are inversely correlated with platelet 
activation conditions, and a cAMP decline contributes to 
activate platelet aggregation.
Combining the COX inhibitor aspirin with a P2Y12 
receptor inhibitor is recommended in many clinical situa-
tions [13]. In particular, this dual antiplatelet association 
is recommended by the clinical guidelines in the current 
treatments of acute coronary syndromes (ACSs). Platelet 
inhibitors are usually given to the patients at the time of 
diagnosis just prior admission to the cardiac catheter lab-
oratory and may be prescribed for long time treatments 
in the follow-up. The primary physiological and pharma-
cological focus of these drugs has been directed towards 
their ability to affect the blood rheology. These drugs 
effectively blunt platelet aggregability and reduce the risk 
of stent thrombosis. However, it has been suggested that 
when combined with a high level of  P2Y12 blockade the 
net effect of higher doses of aspirin could be removal of 
anti-thrombotic and vasodilating prostanoids and so 
a lessening of the anti-thrombotic effectiveness of the 
treatment [14]. Therefore, this association must be used 
with cautions. It is suggested to include in the manage-
ment of ACS the definition of platelet function, in addi-
tion to classical risk factors, in order to set a personalized 
therapy [13].
Fig. 1 Aspirin’s target in platelets: aspirin inhibits cyclo-Oxygenase-1 
(COX-1), limiting thromboxane A2 (TXA2) formation. The thickness of 
line represents the power of aspirin in inhibiting COX, which is about 
200-fold higher for COX-1 than COX-2, whose role in platelet function 
is not clear Fig. 2 Target of oral anti-aggregant drugs in platelets: thienopyridine 
(clopidogrel and prasugrel) and non-thienopyridine (ticagrelor and 
cangrelor) directly or indirectly inhibit ADP receptor  P2Y12, thus limit-
ing adenylate cyclase inhibition and platelet aggregation
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Aspirin resistance in general population
Even if aspirin is a relevant tool to prevent cardiovascular 
events, as shown by meta-analysis of randomized trials 
[15, 16], the occurrence of “aspirin resistance” has been 
described, both as aspirin incapacity to protect individual 
patients from cardiovascular events (i.e., clinical aspirin-
resistance) [17–19] and as aspirin failure to induce a 
given degree of inhibition of platelet responses to ago-
nists or TXA2 synthesis (i.e., laboratory-based aspirin-
resistance) [20]. Indeed, “laboratory aspirin-resistance” 
is correlated to the risk of myocardial infarction and cer-
ebrovascular events, leading to death [21–23].
Surprisingly, the role of the poor responsiveness to 
aspirin in affecting cardiac ischemia/reperfusion (I/R) 
setting has not been deeply investigated so far.
P2Y12 inhibitor resistance in general population
Clinical efficacy may be reduced not only for aspirin, but 
also for  P2Y12 inhibitors. The high inter-individual vari-
ability to clopidogrel inhibitory effects represents a clini-
cal limitation: about 1 on 4 patients shows a suboptimal 
response to the drug [24]. Genetic and environmental fac-
tors can influence the absorption and/or the conversion 
of clopidogrel to its active metabolite. The most impor-
tant cause of clopidogrel resistance has been attributed to 
the inability of cytochromes to metabolize this pro-drug 
to its active metabolite in the liver. However, it has been 
postulated by some authors that an imbalance between 
pro-inflammatory and anti-inflammatory cytokines due 
to altered cytochrome P450 genotypes may contribute to 
impair platelet aggregability, rather than alter the forma-
tion of the active metabolite of clopidogrel [25].
This drug resistance may be overcome with either 
high doses of elinogrel, cilostazol, clopidogrel, prasugrel, 
ticagrelor or Gp IIb/IIIa inhibitors [26]. The problems 
pertaining the  P2Y12 inhibitors resistance are mainly 
described for clopidogrel. For instance, switching from 
clopidogrel to prasugrel was superior to standard treat-
ment with clopidogrel for the achievement of optimal 
antiaggregation within the first 24  h post-angioplasty 
[27].
For details on other drugs the reader is kindly redi-
rected to specific recent literature for drug resistance 
issues [26, 28].
Antiplatelet therapy in type 2 diabetes
The aspirin resistance in diabetes
The policy of antiplatelet therapy in T2DM is still a 
matter of intense debate. Patients with CVDs or with 
high cardiovascular risk profile, because of one or more 
comorbidities, such as diabetes, hypertension and/or 
hyperlipidemia, need early detection and appropriate 
therapies.
In primary prevention of cardiovascular events in 
T2DM potential benefits of aspirin are controversial. An 
Expert Consensus document has established that in pri-
mary prevention aspirin administration is not associated 
with a significant reduction in risk of non-fatal and fatal 
acute myocardial infarction (AMI) and, for this reason, is 
not recommendable in patients with T2DM at low car-
diovascular risk [29].
As said aspirin resistance is not uncommon in the 
general population, and it has been described in great 
prevalence in obese and insulin-resistant patients [30, 
31]. Of note, in the diabetic population aspirin resistance 
is particularly prevalent, inducing doubt about useful-
ness of aspirin for the cardiovascular prevention in this 
condition [32–34]. In fact, placebo-controlled studies 
and post hoc analyses consistently showed that diabetic 
patients receive less benefit from aspirin therapy than the 
non-diabetic population [35, 36]. In particular, a post hoc 
analysis revealed that in diabetic patients aspirin treat-
ment did not cause a significant reduction in the risk of 
CVDs as opposed to subjects with other cardiovascular 
risk factors [37]. This analysis considered a subgroup of 
diabetic patients enrolled in the Italian Primary Preven-
tion Project: a project evaluating the effects of low-dose 
aspirin, 100 mg/day, in the prevention of cardiovascular 
endpoints in patients with one or more risk factors [38]. 
Recently, a Japanese randomized trial (JPAD) has con-
firmed that aspirin fails to reduce the risk of cardiovascu-
lar events in primary prevention, but increases the risk of 
gastrointestinal bleeding [39].
In secondary prevention and in high-risk patients with 
previous AMI, aspirin may reduce the risk of future 
events by about 20% [40], thus justifying therapeutic 
guidelines recommendation on aspirin treatment for pre-
vention of cardiovascular events in adults with diabetes 
and established CVDs. Of note, elevated fasting plasma 
glucose is associated with increased leukocyte-platelet 
aggregate rates, but high risk T2DM patients, without 
prior ischemic events, may have normal blood platelet 
functionality profiles [41]. These observations can explain 
why aspirin has no benefit in primary prevention of well-
controlled diabetes, but is in some way only effective in 
secondary prevention (i.e. after ischemic events).
Indeed, diabetes is associated with reduced rates of 
responsiveness to aspirin and this contributes to explain 
why the reduction of the cardiovascular event risk in dia-
betic patients is lower than in non-diabetic subjects [17]. 
The high prevalence of poor responders to aspirin among 
diabetic individuals (1 in 4 have high on-treatment plate-
let reactivity while using aspirin daily) could therefore 
play a role in the poor cardiovascular outcome in diabetes 
[42–44]. Furthermore, it is possible that a great number 
of diabetic subjects are exposed to the gastrointestinal 
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side effects of aspirin without experiencing the protective 
cardiovascular effects of the drug.
The mechanisms involved in platelet resistance to aspi-
rin in diabetic patients are not completely clarified, even 
if different mechanisms have been hypothesized [45].
P2Y12 inhibitor resistance in diabetes
As said, the concept of “resistance” has been described 
also for the  P2Y12 inhibitor clopidogrel, and it has been 
associated with both modifiable and non-modifiable risk 
factors, including T2DM, body mass index, age, gender, 
smoking, and genetic polymorphisms, such as insulin 
receptor substrate-1 polymorphisms [46].
Particularly, in T2DM, studies have shown that a defect 
in the mechanisms through which insulin interferes 
with signalling by the  P2Y12 receptor could contribute to 
platelet hyper-reactivity [47]. However, a stronger asso-
ciation between poor clinical outcomes of patients on 
treatment with clopidogrel and low platelet inhibition 
was found in T2DM patients compared with non-T2DM 
patients: [48] there are still conflicting reports linking low 
drug response and adverse interactions with clinical out-
comes. A recent meta-analysis of published trial data did 
not suggest a different efficacy of clopidogrel in people 
with vs without diabetes [28].
Nevertheless, these findings do not preclude that both 
diabetic and non-diabetic subjects could have less-than-
expected clinical benefits from clopidogrel treatment. 
For example, using a loading dose of clopidogrel, rather 
than small daily doses, was not enough for overcoming 
enhanced platelet reactivity in subjects with T2DM, sug-
gesting that more effective anti-platelet drugs are neces-
sary for such patients [49]. Of note, when these drugs, 
as well as aspirin, fail to protect individual patients from 
cardiovascular events, frequently costly surgical opera-
tions (e.g. coronary artery bypass, balloon angioplasty 
and stenting) are required to treat CVDs. Therefore, 
further studies are necessary to better understand the 
potentially different benefit-to-risk profile of subjects 
treated with anti-aggregant therapies.
Influence of TD2M on cardioprotection and on IRI
CVDs are the number one cause of death: more peo-
ple die from CVDs than from any other cause. CVDs 
account for about 30–35% of all global deaths. Of these 
18 million deaths, about 45% were due to coronary heart 
disease (CHD) and 35% were due to stroke. About 75% 
of cardiovascular deaths occur in low and middle income 
countries. Of the 16 million deaths, below the age of 70, 
due to non-communicable diseases, 82% are in low and 
middle income countries and 37% are caused by CVDs 
[50]. The immigration from these countries is increasing 
and cost/effective therapies are much needed.
In patients with ST elevation myocardial infarction 
(STEMI), prompt reperfusion with primary PCI is the 
most recommendable intervention to limit infarct size. 
However, it is now clear that IRI are due to both ischemia 
and reperfusion. Indeed, reperfusion injury (the cell death 
resulting from the recovery of oxygen and blood sup-
ply) can contribute to about 50% of the final myocardial 
infarct size, both in experimental and clinical studies 
[51–53]. Limitation of IRI represents a currently unmet 
clinical need.
Indeed, significant myocardial necrosis still occurs 
despite timely reperfusion, and its extent is the main 
prognostic determinant following PCI. Different 
approaches to cardioprotection have been proposed to 
limit infarct size in patients with STEMI during primary 
PCI. Among these, intravenous or intracoronary injec-
tion of drugs or cells have been found safe and effective in 
experimental and clinical studies. However, further stud-
ies are needed to obtain satisfactory clinical results.
Ischemic conditioning
In order to introduce the important concept of car-
dioprotective pathways and the concept of reperfusion 
injury, we report some brief notes on the cardioprotective 
mechanisms induced by ischemic conditioning. These 
brief notes are useful to better understand the following 
paragraphs. The reader is kindly redirected to specific 
literature for more details regarding the cardioprotective 
pathways activated by conditioning procedures [52–55].
Ischemic pre- and postconditioning are potent car-
dioprotective procedures to reduce infarct size due to 
myocardial I/R. It seems that these two conditioning 
protocols target reperfusion injury [52]. These two pro-
tocols trigger complex signalling pathways which start 
from the release of ligands released by ischemic and 
post-ischemic myocardium. This ligands-receptors inter-
action activates complex cascades including membrane 
G-protein, growth factor receptors, signalling enzymes, 
such as nitric oxide synthase (NOS), protein kinase C 
and G (PKC and PKG), as well as ATP-sensitive potas-
sium (KATP) channels, reactive oxygen species (ROS), 
TNF-α and sphingosine-1-phosphate (S1P) [56]. The final 
effector is likely the mitochondrial permeability transi-
tion pore (mPTP) where the signalling cascade prevents 
pore formation leading to protection [57]. This signalling 
pathway could represent a therapeutic target to protect 
patients with AMI.
However, to date the conditioning interventions show-
ing efficacy in reducing IRI in laboratory have been 
unsuccessful in clinical context. The reasons for the 
inability to translate positive results obtained in the 
experimental laboratory to the clinical scenario have 
been discussed in several recent reviews: among the 
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plethora of reasons, the presence of comorbidities and 
related therapies in humans, not considered in animal 
experiments, have been considered several times [51–53, 
58–60].
The increased susceptibility to IRI in diabetes
Diabetes represents an important comorbidity in the 
patients presenting with an ACS. The majority of both 
pre-clinical and clinical data demonstrates that the dia-
betic heart is among the most susceptible to IRI and that 
the cardioprotective effects of ischemic and pharmaco-
logical conditioning are compromised in the presence 
of diabetes. Therefore, diabetic subjects have greater 
probability to develop an acute event and perhaps a lim-
ited possibility to reduce infarct size by cardioprotective 
interventions [61]. The increased susceptibility to IRI in 
the setting of diabetes mellitus is due to several mecha-
nisms, including alteration at mitochondrial level, altered 
production of ROS and impairment of antioxidant 
capacities at various intracellular and extracellular sites. 
The compromised protection is often associated with 
the deficient activation of prosurvival signalling path-
ways, such as Akt, ERK1/2, GSK3β, Janus kinase 2 and 
STAT3. Interestingly, the persistence of hyperglycaemia 
in diabetic conditions has been shown to decrease gen-
eration and release of NO and to increase the expression 
and activity of “phosphatase and tensin homolog deleted 
on chromosome 10″ (PTEN), which may contribute to 
inhibit Akt/NO pathway [62–66].
Also, a reduced availability of adenosine may contrib-
ute to the loss of cardioprotective efficacy by condition-
ing protocols in diabetes [67]. Finally, sarcolemmal and 
mitochondrial KATP channel dysfunction, as well as pro-
longed mPTP opening and ROS-induced ROS release in 
response to  Ca2+ overload in the diabetic myocardium 
have been described [68–70].
Therefore, it is likely that the mitochondria function 
and redox state have fundamental roles in understanding 
the susceptibility to CVDs of patients with diabetes. An 
in-depth description of these aspects of diabetes sensi-
tivity to IRI and loss of mechanisms of protection can be 
found in several recent reviews [60, 67, 71].
Here we will consider the putative role of anti-platelet 
therapies in interfering with cardioprotective interven-
tions in experimental conditions considering the intricate 
role of diabetes and platelets in determining IRI.
Influence of anti‑platelet therapies on IRI
Blockade of platelet aggregation during primary PCI for 
AMI is a standard care to inhibit intravascular coagu-
lation and to minimize stent re-thrombosis. Indeed, 
anticoagulant therapy during primary PCI for AMI is 
routinely applied, and a description of this approach is 
beyond the aim of the present mini-review, the reader is 
kindly redirected to specific literature for issues regard-
ing the anticoagulant effects of these drugs [72, 73].
Here we consider the ability of  P2Y12 inhibitors to 
ameliorate myocardial response to ischemia/reperfu-
sion challenging, which are part of the so-called pleio-
tropic properties of anti-platelet therapies investigated by 
Cohen and Downey group. It is likely that nowadays all 
patients with ACSs are treated with platelet  P2Y12 recep-
tor antagonists. It has been proposed that those patients 
receiving  P2Y12 receptor antagonists are already cardio-
protected through the conditioning pathways outlined 
above. Whether this cardioprotective effect is due to 
an amelioration of platelet function or is due to a direct 
effect on myocardium, is under investigation. Whatever 
the case, if it is true that patients receiving  P2Y12 recep-
tor antagonists are indeed already benefiting from con-
ditioning cardioprotection, to further decrease infarction 
interventions which protect by different mechanisms are 
necessary. Indeed, it has been reported that clopidogrel 
and cangrelor protect the rabbit heart against infarction 
[74]. For both drugs the mechanism is not due to inhibi-
tion of intravascular coagulation, but involves signalling 
pathways activated during reperfusion to prevent reper-
fusion injury. Therefore, it is likely that patients receiving 
 P2Y12 inhibitors before PCI may already be conditioned, 
thus explaining failure of recent clinical trials evaluating 
postconditioning procedures [56, 75].
If antiaggregating therapy protects via a similar signal-
ling pathway of conditioning interventions, then it would 
make any other conditioning procedure that protects via 
the same signalling pathway redundant. Indeed, it has 
been proved that ischemic pre- or post-conditioning do 
not add any further protection to the heart of experi-
mental animals protected with cangrelor. Nevertheless, 
in these animals treated with cangrelor, procedures and 
drugs that use different mechanisms such as mild hypo-
thermia or cariporide, a  Na(+)-H(+) exchange blocker, 
display additional cardioprotective effects. The impor-
tant consequence of these results is that patients with 
AMI who are treated with anti  P2Y12 agents may already 
be in a sort of “conditioned state”. Thus, explaining why 
conditioning procedures had only a modest if any effect 
in recent clinical trials. These studies clearly indicate 
that future research should identify interventions and 
procedures that can enhance the protection obtained by 
antiaggregating therapy and should find a way to opti-
mize  P2Y12 inhibition at reperfusion in all patients [74, 
76].
Recently it has been reported that increasing DNA 
glycosylase/AP lyase repair enzyme activity confers 
cytoprotection in several injury models [77]. There-
fore, the effects of EndoIII, a fusion-protein construct 
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that conveys Endonuclease III, a DNA glycosylase/AP 
lyase, to the mitochondria, were studied in terms of 
infarct size reduction in myocardial IRI model. In this 
study, an i.v. bolus of EndoIII, just prior to reperfusion, 
reduced infarct size. The EndoIII-induced infarct limi-
tation was comparable to that seen with  P2Y12 recep-
tor blocker, cangrelor. Importantly, the combination of 
EndoIII with cangrelor reduced infarct size in an extent 
that was greater than that observed with either cangrelor 
or EndoIII alone. Cardioprotection obtained with can-
grelor but not that obtained with EndoIII was abolished 
by pharmacologic inhibition of adenosine receptors or 
phosphatidylinositol-3 kinase, suggesting different cellu-
lar mechanisms for these two interventions. It seems that 
EndoIII protects the heart from necrosis by avoiding the 
release of pro-inflammatory fragments of mitochondrial 
DNA (mtDNA) into the myocardium. Therefore, EndoIII 
and DNase have been proposed as agents that can be 
administered at reperfusion to add their protective effect 
to those of a  P2Y12 blocker already used in patients, and 
thus should be theoretically effective in patients present-
ing with AMI. Of course, this hypothesis needs to be ver-
ified in appropriate clinical studies [77].
Studies in rodents and primate models [56, 74, 76] 
confirm that platelet  P2Y12 receptor antagonists are car-
dioprotective, and that the mechanism is not due to inhi-
bition of platelet aggregation, but to the ability of these 
agents to trigger the same signal transduction pathway 
of conditioning cardioprotection. The cardioprotec-
tive effects exerted by these drugs are a class-effect. In 
fact, either thienopyridine or non- thienopyridine  P2Y12 
inhibitors have shown similar cardioprotective effect 
when an adequate concentration of the agent was present 
in the blood at the moment of reperfusion [78, 79].
From above one can infer that antiplatelet therapy 
directly protects the myocardium against IRI. However, 
the subtitle mechanism(s) by which platelet  P2Y12 inhib-
itors induce protection remains unclear. The Cohen & 
Downey group provided evidence that this cardiopro-
tection is possible only if whole blood is present in the 
experimental preparation: while both ischemic postcon-
ditioning and cangrelor protect blood-perfused hearts, 
the drug does not protect buffer-perfused hearts, sug-
gesting that the cangrelor requires blood constituents or 
factors to protect. These authors also used an anti-plate-
let antibody to make rats thrombocytopenic and to test 
if that blood-factor resides within the platelets. IRI were 
not different in thrombocytopenic rats, suggesting that 
preventing aggregation alone is not protective. While 
ischemic pre-conditioning could reduce infarct size in 
thrombocytopenic rats, the  P2Y12 inhibitor cangrelor 
could not, strongly suggesting that it protects by inter-
acting with some factor in the platelets. These authors 
confirm that platelet  P2Y12 receptor antagonists protect 
the animal heart, not because of inhibited thrombo-
sis, but through the activation of protective signalling. 
Ischemic preconditioning triggers the phosphorylation 
of sphingosine leading to the formation of S1P, which is 
protective. Therefore, these authors demonstrated that 
in rats treated with dimethylsphingosine to block sphin-
gosine kinase, cangrelor was no longer protective. Thus, 
protective mechanisms activated by cangrelor also 
involve sphingosine kinase, thus demonstrating another 
analogy to conditioning protective mechanism [78, 79].
Importantly, differently from cardioprotection induced 
by pharmacological and ischemic conditioning,  P2Y12 
inhibitor-induced mechanisms can result in significant 
attenuation of IRI in animals with diabetes [79]. These 
last results open an interesting scenario on the role of 
platelets in cardioprotection: one may wonder whether 
there are differences on the effects of platelets on IRI 
depending on whether they are healthy or diabetic.
Influence of healthy and diabetic platelets on IRI
There are clear evidences that healthy platelets have 
cardioprotective properties [80, 81]. Recently we have 
shown that the beneficial potentials of healthy plate-
lets are lost by platelets derived from poorly controlled 
T2DM patients [82].
Platelet hyper-reactivity is a central cause of acceler-
ated atherosclerosis and increased risk of cardiovascular 
events in diabetic patients. The mechanisms leading to 
altered platelet reactivity during diabetes are complex 
and not fully elucidated. Platelet dysfunction may be 
due to the fact that diabetes is associated with oxida-
tive stress and inflammation. These conditions may also 
induce endothelial dysfunction which may promote acti-
vation of platelets by decreasing production of NO, thus 
attenuating platelet reactivity. Oxidative stress within 
platelets may exacerbate this effect by attenuating pro-
duction and activity of NO and promoting platelet acti-
vation [83, 84].
Oxidative stress is considered a major determinant, not 
only of vascular complications, but also of suboptimal 
response to antiplatelet agents in T2DM [85]. Moreo-
ver, platelet activation and inflammation are reciprocally 
related: inflammation favours platelet activation that, in 
turn, induces inflammation [84, 86].
Furthermore, diabetic platelets have enhanced levels 
of platelet identifiers (CD41-PE, CD42b-PE) as well as 
markers indicating platelet activation (CD62P-PE and 
CD63-PE) [87]. Finally, ultrastructural and rheological 
modifications, as well as alteration in plasma compo-
nents, such as reduction of CTRP9 concentration, have 
been described as crucial in platelets hyper-reactivity of 
diabetic subjects or animals [88, 89].
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Overall, there are a number of alterations in diabetic 
platelets, but which ones play a key role in determining 
the impact of diabetes on platelet function, platelet-medi-
ated effects and in platelet response to anti-aggregating 
therapy is still unclear.
Platelets are known to release a variety of factors on 
activation. These factors may contribute to the positive 
effects exerted by platelets in a variety of clinical and 
experimental conditions. For instance, platelets have 
been used for soft-tissue healing of low extremity ulcer 
[90, 91]. They have also been used in association with 
mesenchymal stem cells to promote bone regeneration 
[92–95]. In particular, perfusion of hearts during reperfu-
sion with buffer containing washed rat platelets protected 
hearts against dysfunction from IRI [80]. However, sev-
eral studies have suggested that platelets may contribute 
to initiation and propagation of myocardial IRI [96–98].
Nevertheless, in most of these studies in which plate-
lets seem to play a pathological role there is a concomitant 
pathological condition (comorbidities) which may influ-
ence the outcome. In particular, it seems that a defective 
endothelial function may characterize many of these condi-
tions. In fact, it has been proposed that in the exacerbation 
of myocardial IRI may play a pivotal role the interaction 
between platelets, blood cells and endothelial wall [99, 100].
Among the factors released by platelets, some have 
double edged sword behaviour. They may induce car-
dioprotection (i.e. preconditioning like effects) or may 
induce injury depending on several factors (e.g. concen-
tration and timing of infusion) (Fig.  3). Among variable 
platelet factors that may display double-edged sword 
characteristics in the context of cardioprotection, there 
are Sphingosine-1-Phosphate (S1P), Platelet-activat-
ing factor (PAF) and Chemerin (CHE). We have shown 
that low concentrations of PAF activate the Reperfu-
sion Injury Salvage Kinase (RISK) pathway, including 
PKC, Akt and NOS [101]. This pathway converges on 
mitochondria preventing mPTPs opening at reperfu-
sion [102]. Moreover, we have preliminary evidences of 
S1P alterations in diabetic platelets, and CHE is a predic-
tive marker of CVDs [103]. Indeed, CHE was described 
as a chemo-attractant for leukocyte expressing the 
chemokine-like receptor1 (CMKLR1 or ChemR23). How-
ever, recently, CHE has been identified as an adipokine 
associated with obesity, insulin resistance and metabolic 
syndrome [104]. Several cell types, including adipocytes 
and vascular smooth muscle cells produce CHE as a pre-
cursor converted into a bioactive form by a number of 
serine proteases. Platelets also are an important source of 
CHE, which becomes released in some pathologic con-
ditions [105]. Elevated serum CHE levels are associated 
with ischemic heart disease and CVD in T2DM patients 
[106, 107]. Intriguingly, plasma CHE levels are reduced 
in CVD patients treated with aspirin [108]. Thus, given 
its dual role, CHE deserves to be studied as a possible 
metabo-inflammatory player in obesity-related disorders, 
such as T2DM and CVD.
As said, preliminary experiments have demonstrated 
beneficial role of healthy platelets in the context of myo-
cardial I/R. These beneficial potentials of healthy plate-
lets are lost in platelets derived from T2DM patients. We 
have shown that the effects of platelet-pre-treatment on 
IRI depend on their reactivity status as represented by 
the trend to aggregate which correlates with redox status 
of platelets [109].
We do not know whether or not the platelets of T2DM 
patients taking aspirin or  P2Y12 inhibitor regain their 
cardioprotective properties and/or if this occurs only 
when platelets do not display anti-aggregating resistance. 
We are working on this hypothesis and hope to have an 
answer to this issue in the future.
Conclusions and future perspectives
In summary: (1) diabetes confers a deleterious phenotype 
in patients presenting with ACSs; (2) diabetes may also 
be associated with altered platelet function and response 
to aspirin and other anti-platelet therapies, especially in 
the presence of comorbidities; (3) some  P2Y12 inhibitors 
may remain protective in diabetic patients and animal 
models of diabetes. These are important observations not 
fully understood that require further studies.
Since the prevalence of diabetes in the general popula-
tion is dramatically increasing and since diabetes nega-
tively influences IRI and cardioprotective procedures, the 
management of ischemic heart disease as well as the con-
tinuation of the recent trend of improving cardiovascular 
outcomes from CHD will become increasingly difficult. To 
help to individuate additional drug targets to improve out-
comes of CVDs further, particularly in those patients with 
comorbidities, such as diabetes, it is necessary a better 
comprehension of the differences and similarities between 
the protective mechanisms of the different cardioprotec-
tive strategies, in the various subpopulations of patients. 
In particular, comparative studies on the mechanisms of 
the ischemic conditionings, and on the emerging platelet-
mediated cardioprotection induced by  P2Y12 inhibitors are 
warranted. The intricate interaction between platelet func-
tion, antiplatelet drugs, coronary diseases and IRI in dia-
betes needs to be clarified for enhancing patients benefit 
from antiplatelet therapy and revascularization.
Future perspectives point toward an important role for 
miRNA in platelet function and therapy [110]. Indeed, 
recent studies revealed important roles for miRNA in 
platelet development, function and CVD [111]. miRNAs 
are present in platelet where they interfere with target 
such as c-AMP dependent PKA and receptors, including 
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 P2Y12 and glycoprotein IIb/IIIa. Moreover, activated 
platelets can release functional miRNA that can regu-
late gene expression in cells of the cardiovascular sys-
tem [112]. Several platelet miRNA related to CVD, such 
as miRNA-21 and miRNA-126, are significantly modu-
lated in T2DM and studies are in progress to identify a 
miRNA-based signature associated with T2DM and its 
CVD complications [113]. Interestingly, platelet miRNA 
are responsive to antiplatelet therapy and may represent 
valid biomarker for the response to therapy as emerged 
in recent studies showing that aspirin resistance can 
potentially be identified by miR-92a and miR-19b-1-5p 
levels in plasma [114, 115]. Based on these observations, 
miRNA may become a valuable tool to provide diagnos-
tic and prognostic information about T2DM, coronary 
artery disease complications and therapy responsiveness.
Fig. 3 Among the factors released by platelets, some have double edged sword behavior. Depending on several factors (e.g. concentration and 
timing of infusion), they may induce both cardioprotection (i.e. preconditioning like effects) or injury to cardiomyocytes
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